NVS Quote, Financials, Valuation and Earnings

AstraZeneca PLC has a net margin of 26.48% compared to Novartis AG's net margin of 21.46%. Novartis AG's return on equity of 30.96% beat AstraZeneca PLC's return on equity of 19.55%.

Novartis AG has a consensus price target of $112.64, signalling downside risk potential of -4.61%. On the other hand AstraZeneca PLC has an analysts' consensus of $84.18 which suggests that it could grow by 14.46%. Given that AstraZeneca PLC has higher upside potential than Novartis AG, analysts believe AstraZeneca PLC is more attractive than Novartis AG.

Novartis AG has a beta of 0.595, which suggesting that the stock is 40.528% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.385, suggesting its less volatile than the S&P 500 by 61.545%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 3.38%. AstraZeneca PLC offers a yield of 2.11% to investors and pays a quarterly dividend of $1.05 per share. Novartis AG pays 63.85% of its earnings as a dividend. AstraZeneca PLC pays out 65.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than AstraZeneca PLC quarterly revenues of $13.6B. Novartis AG's net income of $3.6B is higher than AstraZeneca PLC's net income of $2.9B. Notably, Novartis AG's price-to-earnings ratio is 18.48x while AstraZeneca PLC's PE ratio is 29.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.47x versus 4.18x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.

Regulus Therapeutics has a net margin of 26.48% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 30.96% beat Regulus Therapeutics's return on equity of --.

Novartis AG has a consensus price target of $112.64, signalling downside risk potential of -4.61%. On the other hand Regulus Therapeutics has an analysts' consensus of $8.80 which suggests that it could grow by 7.06%. Given that Regulus Therapeutics has higher upside potential than Novartis AG, analysts believe Regulus Therapeutics is more attractive than Novartis AG.

Novartis AG has a beta of 0.595, which suggesting that the stock is 40.528% less volatile than S&P 500. In comparison Regulus Therapeutics has a beta of 0.354, suggesting its less volatile than the S&P 500 by 64.643%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 3.38%. Regulus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 63.85% of its earnings as a dividend. Regulus Therapeutics pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than Regulus Therapeutics quarterly revenues of --. Novartis AG's net income of $3.6B is higher than Regulus Therapeutics's net income of -$9.6M. Notably, Novartis AG's price-to-earnings ratio is 18.48x while Regulus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.47x versus -- for Regulus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of 26.48% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 30.96% beat Roche Holding AG's return on equity of 23.8%.

Novartis AG has a consensus price target of $112.64, signalling downside risk potential of -4.61%. On the other hand Roche Holding AG has an analysts' consensus of $46.42 which suggests that it could grow by 15.58%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Novartis AG has a beta of 0.595, which suggesting that the stock is 40.528% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.459, suggesting its less volatile than the S&P 500 by 54.134%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 3.38%. Roche Holding AG offers a yield of 3.46% to investors and pays a quarterly dividend of $1.39 per share. Novartis AG pays 63.85% of its earnings as a dividend. Roche Holding AG pays out 92.43% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than Roche Holding AG quarterly revenues of --. Novartis AG's net income of $3.6B is higher than Roche Holding AG's net income of --. Notably, Novartis AG's price-to-earnings ratio is 18.48x while Roche Holding AG's PE ratio is 27.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.47x versus 3.68x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.

Sanofi SA has a net margin of 26.48% compared to Novartis AG's net margin of 17.65%. Novartis AG's return on equity of 30.96% beat Sanofi SA's return on equity of 8.47%.

Novartis AG has a consensus price target of $112.64, signalling downside risk potential of -4.61%. On the other hand Sanofi SA has an analysts' consensus of $64.10 which suggests that it could grow by 29.74%. Given that Sanofi SA has higher upside potential than Novartis AG, analysts believe Sanofi SA is more attractive than Novartis AG.

Novartis AG has a beta of 0.595, which suggesting that the stock is 40.528% less volatile than S&P 500. In comparison Sanofi SA has a beta of 0.503, suggesting its less volatile than the S&P 500 by 49.662%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 3.38%. Sanofi SA offers a yield of 4.44% to investors and pays a quarterly dividend of $2.20 per share. Novartis AG pays 63.85% of its earnings as a dividend. Sanofi SA pays out 84.6% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than Sanofi SA quarterly revenues of $11.2B. Novartis AG's net income of $3.6B is higher than Sanofi SA's net income of $2B. Notably, Novartis AG's price-to-earnings ratio is 18.48x while Sanofi SA's PE ratio is 17.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.47x versus 2.54x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.